Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

被引：20

作者：

Loibl, Sibylle ^{[1
,2
]}

Huang, Chiun-Sheng ^{[3
,4
]}

Mano, Max S. ^{[5
]}

Mamounas, Eleftherios P. ^{[6
,7
]}

Geyer, Charles E. ^{[8
,9
]}

Untch, Michael ^{[10
,11
]}

Thery, Jean-Christophe ^{[12
]}

Schwaner, Ingo

Limentani, Steven ^{[13
]}

Loman, Niklas ^{[14
]}

Lubbe, Kristina ^{[15
]}

Chang, Jenny C. ^{[16
]}

Hatschek, Thomas ^{[17
]}

Tesarowski, David ^{[18
]}

Song, Chunyan ^{[18
]}

de Haas, Sanne Lysbet ^{[19
]}

Boulet, Thomas ^{[19
]}

Lambertini, Chiara ^{[19
]}

Wolmark, Norman ^{[8
,20
]}

机构：

[1] GBG, Neu Isenburg, Germany

[2] Ctr Haematol & Oncol Bethanien, Frankfurt, Germany

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[5] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[6] NSABP Fdn, Orlando, FL USA

[7] Orlando Hlth Canc Inst, Orlando, FL USA

[8] NSABP Fdn, Pittsburgh, PA USA

[9] Univ Pittsburgh, Hillman Canc Ctr, Pittsburgh, PA USA

[10] AGO B, Berlin, Germany

[11] HELIOS Klinikum Berlin Buch, Berlin, Germany

[12] Ctr Henri Becquerel, Canc Ctr, Rouen, France

[13] Atrium Hlth, Charlotte, NC USA

[14] Skane Univ Hosp, Lund, Sweden

[15] Diakovere Henrietten Stift, Hannover, Germany

[16] Houston Methodist Canc Ctr, Houston, TX USA

[17] Karolinska Univ Hosp, Solna, Sweden

[18] Genentech Inc, San Francisco, CA 94080 USA

[19] F Hoffmann La Roche Ltd, Basel, Switzerland

[20] Univ Pittsburgh, Pittsburgh, PA USA

来源：

NPJ BREAST CANCER | 2022年 / 8卷 / 01期

关键词：

NEOADJUVANT CHEMOTHERAPY; HER2; PROGNOSIS;

D O I：

10.1038/s41523-022-00477-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.

引用

页数：6

共 50 条

[41] Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
Fonseca Magalhaes Filho, Marcos Aurelio
Aguiar, Pedro Nazareth, Jr.
Mascarenhas Neves, Milena Brachmans
Lopes, Gilberto de Lima, Jr.
del Giglio, Auro
EINSTEIN-SAO PAULO, 2022, 20 : eGS6655
[42] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Piccart-Gebhart, MJ
Procter, M
Leyland-Jones, B
Goldhirsch, A
Untch, M
Smith, I
Gianni, L
Baselga, J
Bell, R
Jackisch, C
Cameron, D
Dowsett, M
Barrios, CH
Steger, G
Huang, CS
Andersson, M
Inbar, M
Lichinitser, M
Láng, I
Nitz, U
Iwata, H
Thomssen, C
Lohrisch, C
Suter, TM
Ruschoff, J
Süto, T
Greatorex, V
Ward, C
Straehle, C
McFadden, E
Dolci, MS
Gelber, RD
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
[43] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, Gunter
Procter, Marion
de Azambuja, Evandro
Zardavas, Dimitrios
Benyunes, Mark
Viale, Giuseppe
Suter, Thomas
Arahmani, Amal
Rouchet, Nathalie
Clark, Emma
Knott, Adam
Lang, Istvan
Levy, Christelle
Yardley, Denise A.
Bines, Jose
Gelber, Richard D.
Piccart, Martine
Baselga, Jose
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
[44] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
Douchet, G.
Richard, Sandrine
ONCOLOGIE, 2018, 20 (01) : 43 - 44
[45] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Mariani, Gabriella
Fasolo, Angelica
De Benedictis, Elena
Gianni, Luca
NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
[46] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
Gabriella Mariani
Angelica Fasolo
Elena De Benedictis
Luca Gianni
Nature Clinical Practice Oncology, 2009, 6 : 93 - 104
[47] Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1425): : 75 - 76
[48] Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?
Ricci, Francesco
Le Tourneau, Christophe
CHINESE CLINICAL ONCOLOGY, 2018, 7 (01)
[49] Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
Geyer, C. E., Jr.
Huang, C-S
Mano, M. S.
Loibl, S.
Mamounas, E. P.
Untch, M.
Wolmark, N.
Rastogi, P.
Fischer, H. H.
Redondo, A.
Jackisch, C.
Jacot, W.
Conlin, A. K.
Schneeweiss, A.
Wapnir, I. L.
Fasching, P. A.
DiGiovanna, M. P.
Wuelfing, P.
Arce-Salinas, C.
Crown, J. P.
Shao, Z.
Caremoli, E. Rota
Wu, H.
Lam, L. H.
Tesarowski, D.
Smitt, M.
Douthwaite, H.
Singel, S. M.
von Minckwitz, G.
CANCER RESEARCH, 2019, 79 (04)
[50] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
Boyraz, Baris
Sendur, Mehmet A. N.
Aksoy, Sercan
Babacan, Taner
Roach, Emir C.
Kizilarslanoglu, Muhammet C.
Petekkaya, Ibrahim
Altundag, Kadri
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414

← 1 2 3 4 5 →